PL1666496T3 - Kompozyt interferonu beta - Google Patents

Kompozyt interferonu beta

Info

Publication number
PL1666496T3
PL1666496T3 PL04772408T PL04772408T PL1666496T3 PL 1666496 T3 PL1666496 T3 PL 1666496T3 PL 04772408 T PL04772408 T PL 04772408T PL 04772408 T PL04772408 T PL 04772408T PL 1666496 T3 PL1666496 T3 PL 1666496T3
Authority
PL
Poland
Prior art keywords
interferon
beta composite
beta
composite
Prior art date
Application number
PL04772408T
Other languages
English (en)
Inventor
Hideki Narumi
Yoshiaki Tsushima
Koji Yamashita
Saburou Sone
Miyuki Sato
Tadatsugu Taniguchi
Original Assignee
Toray Industries
Tadatsugu Taniguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Tadatsugu Taniguchi filed Critical Toray Industries
Publication of PL1666496T3 publication Critical patent/PL1666496T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL04772408T 2003-08-25 2004-08-24 Kompozyt interferonu beta PL1666496T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003299850 2003-08-25
EP04772408.3A EP1666496B1 (en) 2003-08-25 2004-08-24 Interferon-beta composite
PCT/JP2004/012452 WO2005019260A1 (ja) 2003-08-25 2004-08-24 インターフェロンβ複合体

Publications (1)

Publication Number Publication Date
PL1666496T3 true PL1666496T3 (pl) 2014-08-29

Family

ID=34213782

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04772408T PL1666496T3 (pl) 2003-08-25 2004-08-24 Kompozyt interferonu beta

Country Status (11)

Country Link
US (2) US7691975B2 (pl)
EP (1) EP1666496B1 (pl)
JP (1) JP4850514B2 (pl)
KR (1) KR101157679B1 (pl)
CN (2) CN101880326B (pl)
AU (1) AU2004266969B2 (pl)
CA (1) CA2536643C (pl)
ES (1) ES2452640T3 (pl)
PL (1) PL1666496T3 (pl)
PT (1) PT1666496E (pl)
WO (1) WO2005019260A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116948A1 (en) * 2005-04-30 2006-11-09 Chengdu Institute Of Biological Products Interleukin-6 polyethylene glycol conjugate and its preparing method and use
AU2008340058A1 (en) 2007-12-20 2009-07-02 Merck Serono S.A. PEG-interferon-beta formulations
GB0912485D0 (en) 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
SG10201602076QA (en) 2011-10-01 2016-04-28 Glytech Inc Glycosylated polypeptide and pharmaceutical composition containing same
CN104136038A (zh) * 2012-02-29 2014-11-05 东丽株式会社 体腔积液抑制剂
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
JP2017100946A (ja) * 2014-03-28 2017-06-08 東レ株式会社 悪液質の治療剤又は予防剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AR020315A1 (es) * 1997-12-19 2002-05-08 Serono Lab Un complejo de interferon tipo i(ifn) y una subunidad del receptor del interferon humano-(ifnar) que es capaz de unirse al inf tipo i del complejo, una molecula de adn, un vector, una celula huesped incapaz de conducir a la regeneracion de un animal o una planta transformada con un vector, una compo
TR200101086T2 (tr) 1998-10-16 2001-08-21 Biogen, Inc. Interferon beta-1A'nın polimer birleşikleri ve kullanımları.
CA2382066C (en) * 1999-08-20 2006-11-21 Honeybaked Ham, Inc. Apparatus for coating meat
CN1501815A (zh) 1999-08-27 2004-06-02 新的干扰素β-样分子
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
JP4593048B2 (ja) 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
JP2004035515A (ja) 2002-07-05 2004-02-05 Toray Ind Inc インターフェロンβ複合体の製造方法

Also Published As

Publication number Publication date
WO2005019260A1 (ja) 2005-03-03
US20100145017A1 (en) 2010-06-10
US7691975B2 (en) 2010-04-06
AU2004266969A1 (en) 2005-03-03
CN101880326A (zh) 2010-11-10
CN100519581C (zh) 2009-07-29
CN101880326B (zh) 2018-02-16
EP1666496A1 (en) 2006-06-07
CA2536643A1 (en) 2005-03-03
CN1871257A (zh) 2006-11-29
AU2004266969B2 (en) 2010-02-25
KR20060134905A (ko) 2006-12-28
PT1666496E (pt) 2014-06-24
JPWO2005019260A1 (ja) 2007-11-01
US20060246034A1 (en) 2006-11-02
JP4850514B2 (ja) 2012-01-11
CA2536643C (en) 2013-11-12
KR101157679B1 (ko) 2012-06-20
ES2452640T3 (es) 2014-04-02
US7915386B2 (en) 2011-03-29
EP1666496A4 (en) 2006-09-13
EP1666496B1 (en) 2014-03-12

Similar Documents

Publication Publication Date Title
GB2409458B (en) Composite materials
GB2386836B (en) Anti-cancer combinations
GB0322140D0 (en) Combinations
PL371113A1 (pl) Profil zespolony
GB0307975D0 (en) Composite structure
HU0900090V0 (en) Brick composite
GB0324483D0 (en) Composite material
GB0321699D0 (en) Fibre-plastics composite
GB2421742B (en) Structural arrangement
PT1666496E (pt) Composto de interferão β
GB0220510D0 (en) Composite board
GB0510737D0 (en) Rigid composite structure
EP1701926A4 (en) ORGANIC-INORGANIC COMPOSITE
GB0208304D0 (en) Composite structures
GB0414399D0 (en) Composite material
GB2449782B (en) Composite materials
GB0401752D0 (en) Cabin
GB0306072D0 (en) Laminate
GB0318333D0 (en) Laminate
GB0313210D0 (en) Composite structure
GB0222115D0 (en) Improved composite structures
GB0321391D0 (en) Flexi-facial plus
TW566336U (en) Honeycomb-paper-core type composite sheet
GB0329865D0 (en) Composite rail
GB0325288D0 (en) Composite structural component improvements